Brian Van Tine

Associate Prof.

Washington University in St. Louis

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Brian Van Tine is an Associate Professor at Washington University in St. Louis, USA. His research primarily focuses on the molecular mechanisms underlying various cancers, with recent publications emphasizing treatments for pancreatic cancer, osteosarcoma, and sarcomas. He is actively involved in studying innovative therapeutic strategies, including targeted vaccines and novel drug combinations.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (13)

Lan Gao

UNITED STATES

View details

Mohammed Milhem

Oncology Section Chief

University of Iowa Healthcare

UNITED STATES

View details

Angela C. Hirbe

Washington University School of Medicine

UNITED STATES

View details

Anthony Olszanski

Vice Chair Research; Associate Professor

UNITED STATES

View details

Washington University in St. Louis

UNITED STATES

View details

Edwin Choy

Associate Professor

Harvard Medical School

UNITED STATES

View details

Keith Skubitz

Professor

University of Minnesota

UNITED STATES

View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Brian Van Tine

Research Interests

Explore related searches

Contact this professor

About

Articles (24)

PHGDH inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma

Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death

KPNA2 promotes osteosarcoma progression by regulating the alternative splicing of DDX3X mediated by YBX1

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma

Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma

Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?

A phase 2 study of a brachyury‐targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma

Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma

Cytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress

High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance

Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma

The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma

A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy

Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis

Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial

Are the Pieces Starting to Come Together for Management of Desmoid Tumors?

In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Collaborators (13)

Lan Gao

Mohammed Milhem

Angela C. Hirbe

Anthony Olszanski

David S. Hong

J Andrew Livingston

Robin Jones

Varun Monga

VINOD RAVI

Toshinao Oyama

Edwin Choy

Keith Skubitz

Costas A. Lyssiotis

Make your next move.